Hims & Hers boasts excellent underlying performance, but the stock's current valuation remains uncomfortably high. Despite a 40% drop in stock price, shares are not yet a value, and selling put ...

In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against other best telehealth stocks to buy right now. According to Grand View Research ...

This Zacks Rank #2 (Buy) company’s shares have surged 167.4% year to date compared with the industry’s 19.1% growth. The S&P 500 Index has increased 0.8% in the same time frame. HIMS, a ...

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company ...

Hims & Hers Health announced on Tuesday it will bundle Wegovy with the telehealth platform’s membership through a new collaboration with drugmaker Novo Nordisk. The bundle will offer Novo ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

While there's still plenty of work to be done, Hims is one of many such companies that's helping to expand healthcare options, by opening the conversation around men's health, in particular.

She regularly appears on CBS News 24/7 to discuss her reporting. Direct-to-consumer pharmaceutical startup Hims & Hers Health said it is selling injectable GLP-1 weight loss drugs for a fraction ...

Listen to more stories on the Noa app. The ad that Hims & Hers Health plans to air during the Super Bowl comes at you with rapid-fire visual overload—a giant jiggling belly, bare feet on scales ...

Most Super Bowl commercials aim to entertain. A minute-long Big Game ad from telehealth company Hims & Hers Health might do something very different. The spot, slated to air during the third ...